Loris Rizzello
Overview
Explore the profile of Loris Rizzello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
623
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ding H, Liu S, Du W, Su L, Chen J, Tian Y, et al.
Biosens Bioelectron
. 2023 Jun;
236:115446.
PMID: 37290288
Micronucleus (MN) is regarded as an abnormal structure in eukaryotic cells which can be used as a biomarker for genetic instability. However, direct observation of MN in living cells is...
12.
Mori M, Stelitano G, Cazzaniga G, Gelain A, Tresoldi A, Cocorullo M, et al.
Pharmaceutics
. 2023 Feb;
15(2).
PMID: 36839823
Targeting pathogenic mechanisms, rather than essential processes, represents a very attractive approach for the development of new antimycobacterial drugs. In this context, iron acquisition routes have recently emerged as potentially...
13.
Bellosta S, Selmin F, Magri G, Castiglioni S, Procacci P, Sartori P, et al.
Mol Pharm
. 2022 Oct;
19(11):4333-4344.
PMID: 36250999
Drug-eluting nanoparticles (NPs) administered by an eluting balloon represent a novel tool to prevent restenosis after angioplasty, even if the selection of the suitable drug and biodegradable material is still...
14.
Bloise E, Di Bello M, Mele G, Rizzello L
Nanoscale Adv
. 2022 Sep;
1(3):1193-1199.
PMID: 36133209
The possibility of exploring basic biological phenomena requires the development of new and efficient bio-imaging tools. These should ideally combine the feasibility of production (potentially through the use of green...
15.
Mori M, Stelitano G, Griego A, Chiarelli L, Cazzaniga G, Gelain A, et al.
Pharmaceuticals (Basel)
. 2022 Aug;
15(8).
PMID: 36015139
Tuberculosis (TB) causes millions of deaths every year, ranking as one of the most dangerous infectious diseases worldwide. Because several pathogenic strains of () have developed resistance against most of...
16.
Acosta-Gutierrez S, Matias D, Avila-Olias M, Gouveia V, Scarpa E, Forth J, et al.
ACS Cent Sci
. 2022 Aug;
8(7):891-904.
PMID: 35912343
Phenotypic targeting requires the ability of the drug delivery system to discriminate over cell populations expressing a particular receptor combination. Such selectivity control can be achieved using multiplexed-multivalent carriers often...
17.
Maiorano G, Guido C, Russo A, Giglio A, Rizzello L, Testini M, et al.
Pharmaceutics
. 2022 Jul;
14(7).
PMID: 35890206
The development of nanovectors for precise gene therapy is increasingly focusing on avoiding uncontrolled inflammation while still being able to effectively act on the target sites. Herein, we explore the...
18.
Wu Q, Chen Y, Li Q, Chen J, Mo J, Jin M, et al.
Adv Sci (Weinh)
. 2022 Apr;
9(21):e2200999.
PMID: 35470595
Lack of adequate effector T cells infiltrated in tumor is one of the main problems in the failure of immune checkpoint blockade therapy (ICBT). Photodynamic therapy (PDT) induced acute inflammation...
19.
Cascione M, Rizzello L, Manno D, Serra A, De Matteis V
Materials (Basel)
. 2022 Feb;
15(3).
PMID: 35160720
The use of silver nanoparticles (Ag NPs) in the biomedical field deserves a mindful analysis of the possible inflammatory response which could limit their use in the clinic. Despite the...
20.
Pepe G, Sfogliarini C, Rizzello L, Battaglia G, Pinna C, Rovati G, et al.
Biomed Pharmacother
. 2021 Oct;
144:112274.
PMID: 34653752
Sex differences in immune-mediated diseases are linked to the activity of estrogens on innate immunity cells, including macrophages. Tamoxifen (TAM) is a selective estrogen receptor modulator (SERM) used in estrogen...